Immunomedics Inc. (NASDAQ:IMMU) traded up 3.6% during trading on Friday . The company traded as high as $2.28 and last traded at $2.28, with a volume of 607,062 shares changing hands. The stock had previously closed at $2.20.

A number of equities research analysts have recently commented on the company. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Immunomedics in a research report on Tuesday, May 24th. Jefferies Group reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Immunomedics in a research report on Monday, June 6th. Finally, Zacks Investment Research downgraded Immunomedics from a “buy” rating to a “sell” rating in a research report on Tuesday, May 10th.

The company’s 50 day moving average price is $2.95 and its 200 day moving average price is $2.78. The firm’s market capitalization is $216.15 million.

Immunomedics (NASDAQ:IMMU) last released its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by $0.02. On average, analysts expect that Immunomedics Inc. will post ($0.57) EPS for the current year.

In other Immunomedics news, CEO Cynthia L. Goldenberg sold 371,990 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $3.03, for a total value of $1,127,129.70. Following the completion of the sale, the chief executive officer now directly owns 650,396 shares in the company, valued at $1,970,699.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman David M. Goldenberg sold 353,010 shares of the company’s stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $3.88, for a total value of $1,369,678.80. Following the completion of the sale, the chairman now owns 2,602,063 shares of the company’s stock, valued at $10,096,004.44. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Immunomedics stock. Marshall Wace LLP bought a new position in Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned 0.90% of Immunomedics as of its most recent filing with the SEC.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.